FIVE PRIME THERAPEUTICS INC's ticker is FPRX and the CUSIP is 33830X104. A total of 171 filers reported holding FIVE PRIME THERAPEUTICS INC in Q2 2016. The put-call ratio across all filers is 12.90 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $3,303,000,000 | +10177.2% | 547,712 | -77.2% | 0.37% | -88.5% |
| Q1 2019 | $32,139,000 | +44.1% | 2,398,409 | 0.0% | 3.18% | +12.8% |
| Q4 2018 | $22,305,000 | -2.8% | 2,398,409 | +45.6% | 2.82% | -21.1% |
| Q3 2018 | $22,937,000 | +15.1% | 1,647,753 | +30.8% | 3.58% | +29.5% |
| Q2 2018 | $19,921,000 | -99.9% | 1,260,000 | +45.1% | 2.76% | +24.7% |
| Q1 2018 | $14,914,000,000 | +265604.6% | 868,100 | +459.1% | 2.22% | +98.7% |
| Q1 2017 | $5,613,000 | -76.0% | 155,265 | -73.0% | 1.12% | -86.7% |
| Q1 2016 | $23,362,000 | -1.2% | 575,000 | +0.9% | 8.38% | -15.5% |
| Q4 2015 | $23,641,000 | +25.2% | 569,658 | -53.6% | 9.92% | +32.8% |
| Q3 2015 | $18,880,000 | +12.0% | 1,226,785 | +80.8% | 7.47% | +13.7% |
| Q2 2015 | $16,856,000 | – | 678,595 | – | 6.57% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eventide Asset Management | 601,000 | $24,587,000 | 1.39% |
| HealthCor Management, L.P. | 1,010,930 | $41,357,000 | 1.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 86,500 | $3,535,000 | 1.38% |
| PURA VIDA INVESTMENTS, LLC | 75,000 | $3,068,000 | 0.90% |
| BB BIOTECH AG | 777,500 | $31,808,000 | 0.88% |
| AWM Investment Company, Inc. | 100,000 | $4,091,000 | 0.71% |
| Granite Point Capital Management, L.P. | 50,000 | $2,046,000 | 0.43% |
| Rock Springs Capital Management LP | 217,700 | $8,906,000 | 0.41% |
| Crestline Management, LP | 50,919 | $2,083,000 | 0.29% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2,432,700 | $99,522,000 | 0.24% |